Joseph LaRosa - Regeneron Pharmaceuticals Senior Vice President General Counsel, Secretary
REGN Stock | USD 973.80 5.80 0.60% |
President
Mr. Joseph J. LaRosa is an Senior Vice President, General Counsel, Secretary of the Company. Mr. LaRosa was Senior Vice President, General Counsel, and Secretary at Nycomed US Inc. Mr. LaRosas prior experience includes working in a number of senior legal positions at ScheringPlough Corporation from 1993 to 2009, where he was a corporate officer and served most recently as Vice President, Legal Affairs, and a member of the Operations Management Team since 2019.
Age | 65 |
Tenure | 5 years |
Address | 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 |
Phone | 914 847 7000 |
Web | https://www.regeneron.com |
Regeneron Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0774 % which means that it generated a profit of $0.0774 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1528 %, meaning that it created $0.1528 on every $100 dollars invested by stockholders. Regeneron Pharmaceuticals' management efficiency ratios could be used to measure how well Regeneron Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 12th of May 2024, Return On Tangible Assets is likely to grow to 0.13. Also, Return On Capital Employed is likely to grow to 0.14. At this time, Regeneron Pharmaceuticals' Net Tangible Assets are very stable compared to the past year. As of the 12th of May 2024, Return On Tangible Assets is likely to grow to 0.13, while Other Current Assets are likely to drop about 203.9 M.Similar Executives
Showing other executives | PRESIDENT Age | ||
Michael Benkowitz | United Therapeutics | 52 | |
Doug Langa | Novo Nordisk AS | 52 | |
Erik Harris | Ultragenyx | 53 | |
Frank Bennett | Ionis Pharmaceuticals | 67 | |
Douglas Langa | Novo Nordisk AS | 58 | |
Ludovic Helfgott | Novo Nordisk AS | 50 | |
Meredith Kaya | Apellis Pharmaceuticals | N/A | |
Laura SeppLorenzino | Intellia Therapeutics | 63 | |
Xiaobin Wu | BeiGene | 62 | |
Henrik Wulff | Novo Nordisk AS | 54 | |
Karsten Knudsen | Novo Nordisk AS | 53 | |
Camilla Sylvest | Novo Nordisk AS | 52 | |
Maziar Doustdar | Novo Nordisk AS | 54 | |
Kevin Fitzgerald | Alnylam Pharmaceuticals | 55 | |
Kelley Boucher | Alnylam Pharmaceuticals | N/A | |
Wade Walke | Ionis Pharmaceuticals | N/A | |
Victoria Brown | Apellis Pharmaceuticals | 44 | |
Dashyant Dhanak | Incyte | 63 | |
Suma Krishnan | Krystal Biotech | 59 |
Management Performance
Return On Equity | 0.15 | ||||
Return On Asset | 0.0774 |
Regeneron Pharmaceuticals Leadership Team
Elected by the shareholders, the Regeneron Pharmaceuticals' board of directors comprises two types of representatives: Regeneron Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regeneron. The board's role is to monitor Regeneron Pharmaceuticals' management team and ensure that shareholders' interests are well served. Regeneron Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regeneron Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Marion McCourt, Senior Vice President and Head of Commercial | ||
Robert Landry, CFO and Sr. VP of Fin. | ||
Patrice Gilooly, Senior Operations | ||
Andrew Murphy, Executive Research | ||
Christopher CPA, Head Finance | ||
Ryan Crowe, Senior Analysis | ||
Joseph LaRosa, Senior Vice President General Counsel, Secretary | ||
Christopher Fenimore, Vice President Controller | ||
Bob McCowan, Senior Officer | ||
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply | ||
Gerald Underwood, Senior Operations |
Regeneron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Regeneron Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.15 | ||||
Return On Asset | 0.0774 | ||||
Profit Margin | 0.29 % | ||||
Operating Margin | 0.24 % | ||||
Current Valuation | 97.24 B | ||||
Shares Outstanding | 108.37 M | ||||
Shares Owned By Insiders | 1.69 % | ||||
Shares Owned By Institutions | 89.60 % | ||||
Number Of Shares Shorted | 1.57 M | ||||
Price To Earning | 15.51 X |
Currently Active Assets on Macroaxis
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for Regeneron Stock analysis
When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Earnings Share 33.89 | Revenue Per Share 122.574 | Quarterly Revenue Growth (0.01) | Return On Assets 0.0774 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.